Pharmacology and pharmacokinetics of tazemetostat

Area of Science:

• Oncology
• Pharmacology
• Epigenetics

Background:

• Tazemetostat is a novel oral selective inhibitor of enhancer of zeste homolog 2 (EZH2).
• EZH2 inhibition is a therapeutic strategy for certain cancers, including epithelioid sarcoma and EZH2-mutated follicular lymphoma.
• FDA approval in 2020 was based on accelerated approval pathways utilizing objective response rate and duration of response from Phase 2 trials.

Purpose of the Study:

• To review the pharmacology, pharmacokinetics, and clinical applications of tazemetostat.
• To highlight its mechanism of action as a first-in-class EZH2 inhibitor.
• To discuss its approved indications and ongoing research in combination therapies.

Main Methods:

• Review of preclinical and clinical data on tazemetostat.
• Analysis of its mechanism of action, competing with S-adenosylmethionine (SAM) to inhibit EZH2.
• Evaluation of pharmacokinetic properties including bioavailability, metabolism, excretion, and drug interactions.

Main Results:

• Tazemetostat effectively reduces H3K27me3, a pharmacodynamic marker of EZH2 inhibition.
• It is orally bioavailable with rapid absorption and dose-proportional exposure, unaffected by food or gastric acid reducers.
• Metabolized by CYP3A, with limited CNS penetration; no dose adjustments needed for renal or hepatic dysfunction.

Conclusions:

• Tazemetostat is the first approved EZH2 inhibitor for cancer treatment.
• Its pharmacokinetic profile supports oral administration, with specific considerations for drug interactions (e.g., fluconazole).
• Ongoing studies are exploring tazemetostat in combination therapies for various malignancies.